Answers are grounded in this paper and cite their sources.
We retrospectively analyzed 72 intravenous methylprednisolone (IVMP)-treated patients with moderate to severe alopecia areata to assess predictors of ≥ 50% improvement in the Severity of Alopecia Tool score at 6 months, the predictive value of 3-month hair regrowth and exploratory long-term outcomes. At 6 months, 39 patients (54.2%) responded. Shorter disease duration was associated with response (OR: per 1-unit increase in ln(months): 0.69, 95% CI: 0.51-0.95; p = 0.021), as was treatment within 6 months (OR: 4.89, 95% CI: 1.76-13.63; p = 0.002). After excluding possible self-healing acute diffuse and total alopecia cases, the adjusted association between disease duration and 6-month treatment response was no longer significant (OR: 0.74, 95% CI: 0.54-1.02; p = 0.063), whereas treatment initiation within 6 months of disease onset remained significantly associated with response. Among 46 patients with 3-month data, hair regrowth predicted the 6-month response (AUC: 0.872); a 20% threshold yielded 100% specificity and 70.8% sensitivity. Exploratory long-term outcomes were more favorable with shorter disease duration. Three-month hair regrowth may provide an early quantitative indicator of IVMP response, while the independent continuous association between disease duration and outcome warrants further investigation.
No takes yet. Share an insight, caveat, or question.
Ishizaki et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: